A 300 IR sublingual tablet is an effective, safe treatment for house dust mite–induced allergic rhinitis: An international, double-blind, placebo-controlled, randomized phase III clinical trial
Pascal Demoly(Inserm), Thomas B. Casale(University of South Florida), Peter W. Hellings(KU Leuven), Oliver Pfaar(Heidelberg University), Miguel Tortajada‐Girbés(Universitat de València), Peter S. Creticos(Johns Hopkins University), Margitta Worm(Charité - Universitätsmedizin Berlin), Carmen Vidal(Universidade de Santiago de Compostela), Giovanni Passalacqua(Ospedale Policlinico San Martino), F. de Blay(Hôpital Civil, Strasbourg), Philippe Gevaert(Ghent University), Martine Le Gall(Stallergenes Greer (France)), Natalia Nenasheva(Russian Medical Academy of Continuous Professional Education), Krzysztof Kowal(Medical University of Białystok), Jonathan Corren(California Allergy and Asthma Medical Group)
Cited by 96
Related Papers
Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis
|New England Journal of Medicine|2016|2.1k
Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines—2016 revision
|Journal of Allergy and Clinical Immunology|2017|2k
An Official American Thoracic Society/European Respiratory Society Statement: Asthma Control and Exacerbations
|American Journal of Respiratory and Critical Care Medicine|2009|1.9k
Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines: 2010 Revision
|Journal of Allergy and Clinical Immunology|2010|1.8k
Lebrikizumab Treatment in Adults with Asthma
|New England Journal of Medicine|2011|1.5k